Compare GRDN & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | SDGR |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 2024 | 2020 |
| Metric | GRDN | SDGR |
|---|---|---|
| Price | $30.06 | $18.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $32.00 | $26.57 |
| AVG Volume (30 Days) | 310.2K | ★ 776.3K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,389,638,000.00 | $256,951,000.00 |
| Revenue This Year | $19.50 | $23.69 |
| Revenue Next Year | $0.48 | $20.46 |
| P/E Ratio | $110.34 | ★ N/A |
| Revenue Growth | 18.68 | ★ 32.90 |
| 52 Week Low | $17.78 | $15.99 |
| 52 Week High | $37.43 | $28.47 |
| Indicator | GRDN | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 50.16 |
| Support Level | $28.34 | $17.53 |
| Resistance Level | $31.46 | $18.28 |
| Average True Range (ATR) | 1.04 | 0.66 |
| MACD | 0.07 | 0.20 |
| Stochastic Oscillator | 55.02 | 66.25 |
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.